SK15592003A3 - Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie - Google Patents

Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie Download PDF

Info

Publication number
SK15592003A3
SK15592003A3 SK1559-2003A SK15592003A SK15592003A3 SK 15592003 A3 SK15592003 A3 SK 15592003A3 SK 15592003 A SK15592003 A SK 15592003A SK 15592003 A3 SK15592003 A3 SK 15592003A3
Authority
SK
Slovakia
Prior art keywords
acid sequence
antibody
nucleic acid
seq
encoded
Prior art date
Application number
SK1559-2003A
Other languages
English (en)
Slovak (sk)
Inventor
G�Nther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J. Miglietta
Dongen Augustinus Antonius Maria Silvester Van
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals Inc. filed Critical Boehringer Ingelheim International Gmbh
Publication of SK15592003A3 publication Critical patent/SK15592003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SK1559-2003A 2001-05-18 2002-05-17 Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie SK15592003A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (1)

Publication Number Publication Date
SK15592003A3 true SK15592003A3 (sk) 2004-06-08

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1559-2003A SK15592003A3 (sk) 2001-05-18 2002-05-17 Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie

Country Status (18)

Country Link
EP (1) EP1397387A1 (enExample)
JP (1) JP2005504517A (enExample)
CN (1) CN1541226A (enExample)
AR (1) AR036154A1 (enExample)
BR (1) BR0210905A (enExample)
CA (1) CA2443437A1 (enExample)
CZ (1) CZ20033476A3 (enExample)
EA (1) EA200301169A1 (enExample)
EC (1) ECSP034838A (enExample)
EE (1) EE200300569A (enExample)
HU (1) HUP0400030A3 (enExample)
MX (1) MXPA03010523A (enExample)
PE (1) PE20021098A1 (enExample)
PL (1) PL365735A1 (enExample)
SK (1) SK15592003A3 (enExample)
WO (1) WO2002094879A1 (enExample)
YU (1) YU91403A (enExample)
ZA (1) ZA200307365B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
DK2167038T3 (en) * 2007-06-13 2018-08-06 Zymogenetics Inc USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2011212485B2 (en) 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
EA200301169A1 (ru) 2004-06-24
CN1541226A (zh) 2004-10-27
PE20021098A1 (es) 2003-02-11
EE200300569A (et) 2004-04-15
CZ20033476A3 (cs) 2004-05-12
YU91403A (sh) 2006-05-25
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
WO2002094879A1 (en) 2002-11-28
MXPA03010523A (es) 2004-07-01
ECSP034838A (es) 2003-12-24
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
JP2005504517A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
SK15592003A3 (sk) Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie
AU2017268399B2 (en) mRNA combination therapy for the treatment of cancer
JP4421779B2 (ja) 改善された生産性を有するＦＡＰα−特異的抗体
KR102697797B1 (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
AU2025204314A1 (en) Improving the efficacy and safety of adoptive cellular therapies
KR100473836B1 (ko) 천연 인간형화 항체
US7919606B2 (en) Biological products
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
AU2020203990A1 (en) Chimeric receptors and methods of use thereof
KR100655979B1 (ko) 임파구계 종양의 치료제
BG62386B1 (bg) Метод за лечение на в-клетъчна лимфома
US20030068678A1 (en) WISP polypeptides and nucleic acids encoding same
US11993659B2 (en) BCMA targetting antibodies, chimeric antigen receptors, and uses thereof
US20020150559A1 (en) Induction of T cell tolerance with CD40/B7 antagonists
JPH09506507A (ja) Ｃａ５５．１抗原指向性結合構造
NO301075B1 (no) Antistoff som er selektive for TAG-72 for diagnostisk bruk, DNA-sekvens som koder for det, ekspresjonsbærer og celle som kan uttrykke det samt blanding som omfatter antistoffet
ES2234099T3 (es) Anticuerpos monoclanales humanizados anti-alfa beta 3.
PT96509A (pt) Anticorpos recombinantes humanos anti-cd18
US6207815B1 (en) Family of high affinity, modified antibodies for cancer treatment
BRPI0609655A2 (pt) anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
KR20060022646A (ko) Ｓｔｏｐ-1 관련 조성물 및 방법
US20040258616A1 (en) Compositions and methods for treating cancer using IGSF9 and LIV-1
US5645817A (en) Granulocyte-binding antibody constructs, their preparation and use
CN115335396A (zh) 靶向cd33的嵌合抗原受体
JP2002528127A (ja) ヒト化抗−癌腫モノクローナル抗体ｃｃ４９

Legal Events

Date Code Title Description
FC9A Refused patent application